PDP PROGRAM'S INCLUSION OF NOVEL TECHNOLOGIES REQUIRES BASIC PERFORMANCE DATA FROM SPONSORS, ALPERT SAYS; PANEL REVIEW OF PDPs WILL BE CONFIDENTIAL
This article was originally published in The Gray Sheet
Executive Summary
FDA intends to apply product development protocols to novel technologies, but wants product sponsors to provide enough data to allow the agency to commit to a study design, Susan Alpert, director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health, said at an Oct. 22 meeting in Washington, D.C. The PDP conference was sponsored by FDA and the Health Industry Manufacturers Association.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.